Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Core Scientific Inc (CORZ) vs Heron Therapeutics Inc (HRTX) Price & Performance

Core Scientific IncTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Core Scientific Inc vs Heron Therapeutics Inc — how do they compare? Core Scientific Inc trades at $15.11 (market cap $4.94B), while Heron Therapeutics Inc trades at $0.4 (market cap $68.01M). The key difference: Core Scientific Inc is far larger — about 72.6× Heron Therapeutics Inc's market cap, and Core Scientific Inc is more actively traded (15,630,800 versus 1,891,941). Which is the better fit depends on your goals — on Pluang, investors hold Core Scientific Inc for 20 Days and Heron Therapeutics Inc for 35 Days on average.

CORZHRTX
Market Cap
$4.94B$68.01M
Volume
15,630,8001,891,941
Sector
TechnologyHealth
52-Week High
$29.16$1.49
52-Week Low
$13.57$0.27
Typical Hold Time
20 Days35 Days
Enterprise Value
$7.46B$174.75M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Core Scientific Inc

CORZ trades at $15.25, down 4.36% today amid a bearish technical trend. The stock shows weak fundamentals with a net loss of $288.62 million in 2025 and negative profit margins, though revenue is projected to grow to $440 million in 2026. Analyst sentiment remains strongly bullish with an 86% buy rating and a $32.75 consensus price target, but recent earnings misses and high cash burn pose significant risks.

The outlook is mixed: strong analyst support and insider buying suggest confidence in the AI data center strategy, but persistent losses, negative cash flow, and competitive pressures require careful monitoring. The stock's current price near support levels offers potential upside if execution improves, yet volatility and operational challenges present substantial downside risk.

Heron Therapeutics Inc

Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.

The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

CORZ
53% Buy47% Sell
Avg holding period · 20 Days
HRTX
8% Buy92% Sell
Avg holding period · 35 Days

Top news

Latest headlines on both assets

About Core Scientific Inc

Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.

Read more on CORZ →

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX →